ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106; eligible to receive up to USD 960.5 million in future milestones K2 Therapeutics enters into option agreement with Antengene to

INCHEON, South Korea and SAN DIEGO, June 21, 2026 /PRNewswire/ -- LOTTE Biologics announced that it has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea. The milestone was achieved approximately two years after the start of construction in 2024, representing an exceptionally fast project execution timeline among global biologics manufacturing facility construction projects. Continue Reading [Picture] LOTTE Biologics Songdo Bi

SYDNEY and AUCKLAND, New Zealand, June 21, 2026 /PRNewswire/ -- Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne, the company has established active commercial operations and sales channels across the region. The expansion introduces Murj to regional health syste

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million. Syntax Bio expanded its Series A to $14.4 million, bringing total funding to more than $25 million, and added new executive, board and scienti

SHANGHAI, June 20, 2026 /PRNewswire/ -- CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class antiplatelet agent. This milestone marks a critical step toward the New Drug Application (NDA) submission in the United States and brings new hope to millions of patients with cardiovascular and cerebrovascular diseases worldwide. Evategrel (CG-0255) is the l

Scientists at Baylor College of Medicine may have uncovered a promising new way to combat Alzheimer’s and Parkinson’s disease. Instead of trying to stop Tau and alpha-synuclein proteins from gathering into tiny droplets inside brain cells, the researchers found that tubulin—the protein that builds the cell’s internal transport network—can redirect these proteins away from forming toxic clumps and toward healthy, productive work.Scientists at Baylor College of Medicine have identified a potential

Researchers have concluded that nicotine vapes are likely to cause lung and oral cancers, based on evidence ranging from human biomarkers to animal and laboratory studies. The findings challenge the idea that vaping is a harmless alternative to smoking and suggest health risks may be emerging much sooner than many expected.A comprehensive new review led by UNSW Sydney has concluded that nicotine based e-cigarettes are likely to cause cancers of the lungs and oral cavity. Published in the journal

As newborn neurons make their way through the developing brain, they must squeeze through incredibly tight spaces to reach their final destinations. Researchers discovered that this physical journey routinely causes some of the most severe forms of DNA damage—double-strand breaks—yet the young brain has evolved an impressive ability to repair the damage almost immediately.As the brain develops, newly formed neurons must travel through tightly packed tissue to reach their final destinations in th

A study of long-lived families has identified rare genetic variants that may help people stay healthier for much longer as they age. One standout mutation appears to temper inflammation, potentially delaying disease and extending years of healthy living.People age differently. Some remain free of major diseases well into old age, while others develop serious health problems much earlier. Understanding why this happens is becoming increasingly important as populations grow older around the world.

Accenture's work includes AI-enabled drug development support Accenture’s acquisition of Alfahealth could boost AI-driven healthcare in Italy, improving data integration, clinical decision-making and care coordination Healthcare organisations across Italy and Europe are adopting AI to address fragmented data systems and improve care delivery. The technology could enable more integrated clinical workflows and support decision making across hospitals and community providers. As healthcare systems